Dyslipidemia in Type 2 Diabetes (0767-034)

Phase 3TerminatedNCT00547274

Merck Sharp & Dohme LLC111 enrolled

Overview

The purpose of the study is to compare the lipid-altering effects of MK0767, glipizide, and pioglitazone after 12 weeks of treatment. This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

111

Conditions

Diabetes Mellitus, Type II Dyslipidemia

Interventions

MK0767DRUG

Eligibility

Sex: ALLMin age: 21 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Men and non-pregnant females * Age greater than or equal to 21 years * Stop current diabetes therapy (if applicable) * Stop current statin therapy (if applicable) Exclusion Criteria: * History of type 1 diabetes mellitus or ketoacidosis who are currently being treated with insulin * Patients on a weight loss program with ongoing weight loss, or starting an intensive exercise program within the last four weeks * Patients requiring treatment with corticosteroids for more than 14 consecutive days * Patients taking warfarin or warfarin-like anti-coagulants * Patients undergoing surgery within 30 days of Visit 1 * Patients with Hepatitis B, Hepatitis C, active liver or gallbladder disease * Patients with history of pancreatitis or uncontrolled high blood pressure

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.